MISSION STATEMENT

Bovogen Biologicals aims to be a leading global manufacturer of biological fine chemicals derived from bovine by-products or related raw materials.

Our mission is to guarantee that the quality of our products will meet and exceed our specifications each and every time. We also take pride in our ability to surpass customer expectations for quality, product delivery and service.

Bovogen Biologicals’ culture is to become an industry partner with our customers, not just a supplier.

Dr David Kennedy : MBBS, FACSP, FACSM, FASMF

Dr. David Kennedy is a qualified medical practitioner with over 25 years experience and training in musculo-skeletal medicine. He has worked at Stanford University, Mayo Clinic and the University of Toronto. More recently he has been involved in the development and commercialization of a number of Biotechnology companies in Australia and the Asia-Pacific region.

Dr. Kennedy was a founding director of Genesis Biomedical Ltd, President and CEO of Codon AG Tissue Engineering in the Asia Pacific region and a founder, director and COO of CollTech Australia Ltd. He is currently the General Manager of Biotechnology Development Pty Ltd and Australian Biotechnology Park Pty Ltd. He is also the co-founder and director of Felix Capital Investments Limited, a Singapore based capital investment company.
He has lived and worked in North America, Europe and Asia combining his medical and scientific expertise with his commercial and marketing skills.

Dr. Ted Stelmasiak : DVM, PhD, MACVSc

Dr. Stelmasiak is the founder and Chief Executive Officer of Glutagen Pty Ltd, a company specializing in the development of treatments for Coeliacs disease. Dr. Stelmasiak was also a founding Director and former Director of Research of Anadis Limited.

He is veterinary pathologist with over 25 years experience who has published over 60 scientific papers, filed several patents and developed a number of commercially viable biopharmaceutical products.

Dr Neil H. Goss : B.Sc., B.Sc.(Hons), Ph.D.

Dr Goss is Executive Director of Further Options Pty. Ltd., a biotechnology consulting company, and Director of Lynx Biopharmaceutical Pty. Ltd., a company specializing in the sales and marketing of vaccines and plasma products.

He has over 25 years of experience in the plasma fractionation and biotechnology industries and was formerly Director of Research and Development at CSL Bioplasma. Dr Goss has broad experience in scientific, technical and management areas and consults widely to the national and international healthcare community.